On March 19, 2018 Synlogic, Inc., (Nasdaq: SYBX) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, reported that preclinical data from its immuno-oncology (IO) program will be presented at the upcoming annual meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) being held April 14 to 16, 2018, in Chicago (Press release, Synlogic, MAR 19, 2018, View Source [SID1234524892]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The two poster presentations featured at AACR (Free AACR Whitepaper) highlight the application of Synthetic Biotic medicines for the potential treatment of a variety of solid tumors. Abstracts can be found at www.aacr.org

Activation of Innate and Adaptive Immunity via Combinatorial Immunotherapy using Synthetic Biotic Medicines
Abstract Number: LB-131
Session Title:Late-Breaking Research: Immunology 1
Date/Time:Monday, April 16, 2018; 8:00 a.m. – 12:00 p.m. Central Time

Metabolic Modulation of the Tumor Microenvironment using Synthetic Biotic Medicines
Abstract Number: 2920
Session Category: Experimental and Molecular Therapeutics
Session Title: New Targets 2
Date/Time:Monday, April 16, 2018; 1:00 p.m. – 5:00 p.m. Central Time
Session Location:McCormick Place South, Exhibit Hall A, Poster Section 40